Brookline Capital Management Forecasts CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $63.56 for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

Several other equities research analysts have also recently issued reports on CRSP. Bank of America cut their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Chardan Capital reissued a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Stock Down 1.5 %

NASDAQ CRSP opened at $41.29 on Wednesday. The firm has a 50-day moving average price of $46.63 and a two-hundred day moving average price of $48.94. CRISPR Therapeutics has a 12-month low of $38.20 and a 12-month high of $91.10. The company has a market capitalization of $3.52 billion, a P/E ratio of -14.59 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the firm earned ($1.41) earnings per share.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 in the last quarter. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Capital Market Strategies LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at $461,000. Capital Advisors Inc. OK raised its holdings in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after purchasing an additional 22,583 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Granite Bay Wealth Management LLC bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $2,375,000. Finally, State Street Corp boosted its stake in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.